A new Phase I clinical trial provides proof of concept for a potential therapy for treatment-resistant cancers, particularly ...
Engineered nanoparticles can improve cancer immunotherapy by delivering drugs, antigens, and genetic payloads with greater ...
Detailed price information for Geovax Labs Inc (GOVX-Q) from The Globe and Mail including charting and trades.
LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has filed ...
Issued on behalf of GT Biopharma, Inc.After more than $1.7 billion in dealmaking and a string of Phase 1 starts in 2026, prostate, pancreatic, ...
A phase 2 trial evaluated the efficacy of nivolumab added to brachytherapy, external beam radiation therapy, and ADT in men with high-risk grade group 5 prostate cancer.
Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering ...
Researchers Moffitt Cancer Center have reported encouraging early results from a clinical trial testing whether immunotherapy can improve treatment for men with one of the most dangerous forms of ...
Glioblastoma remains one of the most lethal primary brain tumors, with limited durable benefit from current standard-of-care approaches. In parallel, ...
A landmark study led by researchers at Keck Medicine of USC, recently published in the Journal of Vascular Surgery, indicates ...
Dr. Leal introduces amifampridine, an FDA-approved oral potassium channel blocker that increases acetylcholine release at ...
A USC study finds immunotherapy increases PAD risk by 60%. Experts advise vascular monitoring to help prevent limb loss in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results